secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001437749-24-015378
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica dosed first patient in ReMEDy2 stroke trial; Q1 cash $46.5M
---------------------------------------------------------------------

- First participant enrolled in relaunched ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke.
- Cash, equivalents and investments of $46.5M as of March 31, 2024; working capital $44.9M.
- Net cash used in operations was $6.7M in Q1 2024 vs $5.1M in Q1 2023, driven by vendor deposits for ReMEDy2.
- R&D expenses $3.7M (up from $3.6M) and G&A $2.1M (up from $1.9M) compared to year-ago quarter.
- Expect full enrollment for 144-patient interim analysis by Q1 2025; Canadian and Australian site activations on track for H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924015378/0001437749-24-015378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924015378/dmtp20240507_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-015378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer